Investor · 1 deal
Every published round Vertex Ventures HC took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Allay Therapeutics | Series C | 16 Sep 2021 | $60m | Participant | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Vertex Ventures HC has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Allay Therapeutics | 16 Sep 2021, Series C | 1 | 0 |
Fund closes reported for Vertex Ventures HC, as distinct from the investments it has made.
Companies Vertex Ventures HC has backed that another company then bought. An exit for the holding, not a deal Vertex Ventures HC did.
Stories naming Vertex Ventures HC. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
US-Singapore biotech Allay Therapeutics has closed a $60 million Series C round led by Arboretum Ventures, with several healthcare investors taking part, to advance its long-acting post-surgical pain candidate into late-stage trials.
Singapore-based cross-border payments firm InstaReM has closed the first half of its Series C, led by MDI Ventures and Beacon Venture Capital, and is targeting a New York listing in 2021.